We serve Chemical Name:2-methyl-3-(2-furyl)propenal CAS:874-66-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-methyl-3-(2-furyl)propenal
CAS.NO:874-66-8
Synonyms:MFCD00063240;Furfurylidene-2-propanal;FEMA No. 2704;EINECS 212-866-9;3-Furanacrolein,2-methyl;2-Methyl-3-furylacrolein;Furfurylidine-2-propanal;2-Furfurylidenepropionaldehyde
Molecular Formula:C8H8O2
Molecular Weight:136.14800
HS Code:2932190090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:280-281°C
Density:1,097 g/cm3
Index of Refraction:1.6140
PSA:30.21000
Exact Mass:136.05200
LogP:1.88180
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD00063240 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Furfurylidenepropionaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Furfurylidine-2-propanal Use and application,2-Methyl-3-furylacrolein technical grade,usp/ep/jp grade.
Related News: Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business. 2-methyl-3-(2-furyl)propenal manufacturer With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout. 2-methyl-3-(2-furyl)propenal supplier The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 2-methyl-3-(2-furyl)propenal vendor Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business. 2-methyl-3-(2-furyl)propenal factory Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.